Retrospective analyses of CHOPE plus L-asparaginase regimen in treatment of T-cell lymphoma
10.3969/j.issn.1671-167X.2016.05.017
- VernacularTitle:CHOPE方案结合左旋门冬酰胺酶治疗T细胞淋巴瘤的回顾性分析
- Author:
Wenli WAN
;
Jing WANG
;
Mingxia ZHU
;
Wei ZHANG
;
Xiaoyan KE
- Publication Type:Journal Article
- Keywords:
Lymphoma,non-Hodgkin;
Lymphoma,T-cell;
Drug therapy;
Asparaginase;
Survival analysis
- From:
Journal of Peking University(Health Sciences)
2016;48(5):841-845
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate prognostic factors of the T-cell non-Hodgkin’s lymphoma (T-NHL),and to study the clinical efficacy of CHOPE plus L-asparaginase (L-ASP)regimen for T-NHL.Methods:Retrospective analyses were made of 61 T-NHL patients who were treated from July 2007 to August 2013.Randomly divided into two groups CHOPE and CHOPE +L group (Based on CHOPE,added with L-ASP on the 1st,3rd,5th,7th,9th and 11th day).Results:Of the 61 patients evaluatd with the median survival was 22 (3 -65)months,the complete remission rate was 52.50%,the partial remission rate 29.51%,and the response rate 80.01%.The complete remission rate was 57.89%,and the patial remission rate 84.21% in CHOPE +L and the complete remission rate 43.48%,the response rate 78.26% in CHOPE,respectively (both P >0.05).The 1-,2-,and 5-year overall survival rates were 91.0%,87.6% and 65.7% respectively (P >0.05 ).But the overall survival rate in CHOPE +L was significantly higher than that in CHOPE group in extranodal NK/T-cell lymphoma,nasal type (ENKTCL)(P <0.05 ).The analysis of the prognostic factors indicated that ENKTCL,the outside junction lesions,and the CR rate were poor factors with statistic significance in T-NHL.Conclusion:CHOPE +L regimen has better efficacy for ENKTCL,but whether CHOPE +L regimen is used in the treatment of T-NHL,large prospective clinical trials are worth for further investigation.
